logo
  

Health Canada Approves PAXLOVID - Quick Facts

Health Canada has authorized the combination of two antiviral drugs, nirmatrelvir and ritonavir, (PAXLOVID) to treat adults with mild to moderate COVID-19 who are at high risk of progressing to serious disease. The drug is intended for use as soon as possible after diagnosis of COVID-19 and within five days of the start of symptoms.

Health Canada received the submission for PAXLOVIDTM from Pfizer on December 1, 2021, and conducted an expedited review. The company submitted the data to Health Canada on a rolling basis throughout the review process.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Follow RTT